Caris Life Sciences

About Caris Life Sciences

Caris Life Sciences is a leading next-generation AI TechBio company and precision medicine pioneer founded in 2008 with the mission to improve the human condition. The company focuses on revolutionizing healthcare by providing high-quality molecular information to detect, categorize, and treat diseases, particularly cancer, using transformative technologies and massive data sets to advance precision medicine and improve patient outcomes.

Products & Services

Caris Assure:A blood-based assay using whole exome and transcriptome sequencing with a novel circulating Nucleic Acid Sequencing (cNAS) approach, providing deep molecular insights from minimally invasive samples to inform personalized treatment decisions.

Caris MI Profile:Comprehensive tissue-based testing with whole exome sequencing (WES - DNA), whole transcriptome sequencing (WTS - RNA) for over 23,000 genes, protein analysis, and AI-predictive algorithms to guide precise, individualized treatment decisions.

Caris Molecular AI:Utilizes a large multimodal database of molecular and clinical outcomes data, applying AI bioinformatics and machine learning to classify cancer at the molecular level and predict patient responses.

MI Cancer Seek:A clinical test for cancer profiling, available for ordering, focusing on molecular insights.

MI Tumor Seek Hybrid:A hybrid tissue profiling test to provide detailed molecular information for cancer treatment.

Caris GPSai:An AI-powered signature tool for molecular classification and treatment guidance.

Caris FOLFIRSTai:An AI-based tool for predicting treatment responses in specific cancer scenarios.

Specialties

Precision Medicine Molecular Profiling Artificial Intelligence in Healthcare Cancer Care Genomic and Proteomic Data Analysis Biopharma Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Growth Capital T: - FT: Growth Capital	A: 168000000 MR: - FA: $168 million FAN: 168000000	D: 2025-04-07 FD: 2025-04-07	6 investors
2	RT: Senior Secured Debt T: - FT: Senior Secured Debt	A: 400000000 MR: - FA: $400 million FAN: 400000000	D: 2023-01-19 FD: 2023-01-19	2 investors

Growth Capital Latest

2025-04-07

$168.0M

6 investors (Pro only)

Senior Secured Debt 2023-01-19

$400.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

James Hamrick

Chairman, Caris Precision Oncology Alliance

M

Manmeet Ahluwalia

Chief, Solid Tumor Medical Oncology; Deputy Director and Chief Scientific Officer at Miami Cancer Institute

H

Heinz-Josef Lenz

Associate Director for Clinical Research

S

Sagar Lonial

Chief Medical Officer

M

Marcia Cruz-Correa

Executive Director

R

Ruben Mesa

President / Executive Director

View 51 more team members with Pro

Unlock Full Team Directory

Recent News